COH.AU · Cochlear Limited

-

Please sign in to comment on COH.AU

1 Comment

Admin

4 years, 5 months ago

Cochlear Limited is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.

From a valuation standpoint, the stock is 96.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.4.

Cochlear Limited's total revenue sank by 1.7% to $743M since the same quarter in the previous year.

Its net income has increased by 49.8% to $236M since the same quarter in the previous year.

Finally, its free cash flow grew by 1119.6% to $34M since the same quarter in the previous year.

Based on the above factors, Cochlear Limited gets an overall score of 4/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU000000COH5
Sector	Healthcare
Industry	Medical Devices

Market Cap	20B
Target Price	309.9145
Dividend Yield	1.5%
Beta	0.4
PE Ratio	50.11

ABOUT

Cochlear Limited

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories. The company was founded in 1981 and is headquartered in Sydney, Australia.

COH.AU · Cochlear Limited

-

Cochlear Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cochlear Limited using a moving average strategy